TRIM28 inactivation in epithelial nephroblastoma is frequent and often associated with predisposing TRIM28 germline variants

Wilms tumors (WTs) are histologically diverse childhood cancers with variable contributions of blastema, stroma, and epithelia. A variety of cancer genes operate in WTs, including the tripartite‐motif‐containing‐28 gene (TRIM28). Case reports and small case series suggest that TRIM28 mutations are associated with epithelial morphology and WT predisposition. Here, we systematically investigated the prevalence of TRIM28 inactivation and predisposing mutations in a cohort of 126 WTs with >2/3 epithelial cells, spanning 20 years of biobanking in the German SIOP93‐01/GPOH and SIOP2001/GPOH studies. Overall, 44.4% (56/126) cases exhibited loss of TRIM28 by immunohistochemical staining. Of these, 48 could be further analyzed molecularly, revealing TRIM28 sequence variants in each case – either homozygous (~2/3) or heterozygous with epigenetic silencing of the second allele (~1/3). The majority (80%) of the mutations resulted in premature stops and frameshifts. In addition, we detected missense mutations and small deletions predicted to destabilize the protein through interference with folding of key structural elements such as the zinc‐binding clusters of the RING, B‐box‐2, and PHD domains or the central coiled‐coil region. TRIM28‐mutant tumors otherwise lacked WT‐typical IGF2 alterations or driver events, except for rare TP53 progression events that occurred with expected frequency. Expression profiling identified TRIM28‐mutant tumors as a homogeneous subset of epithelial WTs that mostly present with stage I disease. There was a high prevalence of perilobar nephrogenic rests, putative precursor lesions, that carried the same biallelic TRIM28 alterations in 7/7 cases tested. Importantly, 46% of the TRIM28 mutations were present in blood cells or normal kidney tissue, suggesting germline events or somatic mosaicism, partly supported by family history. Given the high prevalence of predisposing variants in TRIM28‐driven WT, we suggest that immunohistochemical testing of TRIM28 be integrated into diagnostic practice as the management of WT in predisposed children differs from that with sporadic tumors. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.

[1]  K. Pritchard-Jones,et al.  Stage I epithelial or stromal type Wilms tumors are low risk tumors: An analysis of patients treated on the SIOP‐WT‐2001 protocol in the UK‐CCLG and GPOH studies (2001–2020) , 2023, Cancer.

[2]  D. Gisselsson,et al.  Tumor biology, biomarkers, and liquid biopsy in pediatric renal tumors , 2023, Pediatric blood & cancer.

[3]  G. Vujanić,et al.  The varied spectrum of nephroblastomatosis, nephrogenic rests, and Wilms tumors: Review of current definitions and challenges of the field , 2022, Pediatric blood & cancer.

[4]  D. Goldstone,et al.  Mapping the interaction between Trim28 and the KRAB domain at the center of Trim28 silencing of endogenous retroviruses , 2022, Protein science : a publication of the Protein Society.

[5]  Y. Modis,et al.  Structure and functional mapping of the KRAB‐KAP1 repressor complex , 2022, bioRxiv.

[6]  S. Behjati,et al.  Wilms tumour , 2021, Nature Reviews Disease Primers.

[7]  S. Behjati,et al.  Maturation Block in Childhood Cancer. , 2021, Cancer discovery.

[8]  R. Kuiper,et al.  TRIM28 variants and Wilms' tumour predisposition , 2021, The Journal of pathology.

[9]  M. Gessler,et al.  Less may be more for stage I epithelial Wilms tumors , 2020, Cancer.

[10]  U. Mayor,et al.  How to Inactivate Human Ubiquitin E3 Ligases by Mutation , 2020, Frontiers in Cell and Developmental Biology.

[11]  S. Mirarab,et al.  Sequence Analysis , 2020, Encyclopedia of Bioinformatics and Computational Biology.

[12]  Matthew D. Young,et al.  Embryonal precursors of Wilms tumor , 2019, Science.

[13]  Y. Modis,et al.  Structure of KAP1 tripartite motif identifies molecular interfaces required for retroelement silencing , 2019, Proceedings of the National Academy of Sciences.

[14]  S. Seal,et al.  Identification of new Wilms tumour predisposition genes: an exome sequencing study , 2019, The Lancet. Child & adolescent health.

[15]  M. Gessler,et al.  TRIM28 haploinsufficiency predisposes to Wilms tumor , 2019, International journal of cancer.

[16]  D. Gerhard,et al.  A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children’s Oncology Group study , 2018, PloS one.

[17]  Keith A. Crandall,et al.  Telescope: Characterization of the retrotranscriptome by accurate estimation of transposable element expression , 2018, bioRxiv.

[18]  Helen M. Rowe,et al.  KAP1 regulates endogenous retroviruses in adult human cells and contributes to innate immune control , 2018, EMBO reports.

[19]  A. Reeve,et al.  Germline mutations and somatic inactivation of TRIM28 in Wilms tumour , 2018, PLoS genetics.

[20]  C. Rübe,et al.  Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP–RTSG 2016 protocol , 2017, Nature Reviews Urology.

[21]  Patrycja Czerwińska,et al.  The complexity of TRIM28 contribution to cancer , 2017, Journal of Biomedical Science.

[22]  Qing-Rong Chen,et al.  A Children's Oncology Group and TARGET Initiative Exploring the Genetic Landscape of Wilms Tumor , 2017, Nature Genetics.

[23]  Marie-Liesse Asselin-Labat,et al.  Glimma: interactive graphics for gene expression analysis , 2017, bioRxiv.

[24]  M. Gessler,et al.  Hey bHLH Proteins Interact with a FBXO45 Containing SCF Ubiquitin Ligase Complex and Induce Its Translocation into the Nucleus , 2015, PloS one.

[25]  R. Eils,et al.  Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors. , 2015, Cancer cell.

[26]  Richard A. Moore,et al.  Recurrent DGCR8, DROSHA, and SIX homeodomain mutations in favorable histology Wilms tumors. , 2015, Cancer cell.

[27]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[28]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[29]  Peggy J. Farnham,et al.  KAP1 Protein: An Enigmatic Master Regulator of the Genome* , 2011, The Journal of Biological Chemistry.

[30]  Helen M. Rowe,et al.  KAP1 controls endogenous retroviruses in embryonic stem cells , 2010, Nature.

[31]  Davis J. McCarthy,et al.  edgeR: a Bioconductor package for differential expression analysis of digital gene expression data , 2009, Bioinform..

[32]  Ming-Ming Zhou,et al.  Structural insights into human KAP1 PHD finger–bromodomain and its role in gene silencing , 2008, Nature Structural &Molecular Biology.

[33]  M. Gessler,et al.  Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis , 2007, Genes, chromosomes & cancer.

[34]  P. Chambon,et al.  Mice lacking the transcriptional corepressor TIF1beta are defective in early postimplantation development. , 2000, Development.

[35]  WILMS' TUMOUR , 1972 .

[36]  N. Kiviat,et al.  Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' tumor. , 1990, Pediatric pathology.